China Pharma Holdings (CPHI) Other Non-Current Liabilities (2010 - 2023)

China Pharma Holdings' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2023.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $2.2 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $2.2 million (changed N/A YoY) and the FY2022 annual result came in at $2.4 million, up 26.85% from the prior year.
• Other Non-Current Liabilities was $2.2 million for Q1 2023 at China Pharma Holdings, down from $2.4 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $3.1 million in Q2 2021 and bottomed at $1.7 million in Q3 2021.
• A 5-year average of $2.3 million and a median of $2.4 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities sank 31.44% — and 2022, when it grew 26.85%.
• China Pharma Holdings' Other Non-Current Liabilities stood at $2.4 million in 2019, then gained by 14.44% to $2.7 million in 2020, then sank by 31.44% to $1.9 million in 2021, then grew by 26.85% to $2.4 million in 2022, then retreated by 9.15% to $2.2 million in 2023.
• Business Quant data shows CPHI's Other Non-Current Liabilities at $2.2 million in Q1 2023, $2.4 million in Q4 2022, and $1.9 million in Q4 2021.